STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNLI
  4. [Form 4] Denali Therapeutics Inc. Insider Trading Activity

Denali Therapeutics (DNLI) director granted RSUs and stock options in new equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options. She acquired 6,408 shares of Common Stock at a price of $0.00 per share as a grant, bringing her direct Common Stock holdings to 32,483 shares.

Each of these 6,408 shares is represented by a restricted stock unit and a contingent right to receive one share of Common Stock, with 100% of the units vesting upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders. She also received a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, which will vest on the same schedule.

Positive

  • None.

Negative

  • None.
Insider Cook Jennifer E.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 19,226 $0.00 --
Grant/Award Common Stock 6,408 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 19,226 shares (Direct, null); Common Stock — 32,483 shares (Direct, null)
Footnotes (1)
  1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Includes 6,408 unvested RSUs. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
RSU shares granted 6,408 shares Restricted Stock Units representing Common Stock grant on June 3, 2026
Post-grant common holdings 32,483 shares Common Stock directly owned after RSU grant
Option shares granted 19,226 shares Stock option covering Common Stock granted on June 3, 2026
Option exercise price $19.66 per share Exercise price for 19,226-share stock option
RSU vesting trigger 1 year / pre-meeting Vests on one-year anniversary or day before next annual meeting
Option expiration June 3, 2036 Expiration date for stock option on Common Stock
Restricted Stock Unit ("RSU") financial
"Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock"
contingent right financial
"and a contingent right to receive one share of common stock of the Issuer"
vest financial
"100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 19.6600"
annual meeting of stockholders financial
"or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cook Jennifer E.
(Last)(First)(Middle)
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026A6,408(1)A$032,483(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$19.6606/03/2026A19,226 (3)06/03/2036Common Stock19,226$019,226D
Explanation of Responses:
1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
2. Includes 6,408 unvested RSUs.
3. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Remarks:
/s/ Tyler Nielsen, by power of attorney06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Denali Therapeutics (DNLI) director Jennifer Cook acquire in this Form 4?

Jennifer Cook received equity compensation grants, not open-market purchases. She acquired 6,408 shares of Common Stock through restricted stock units and a stock option covering 19,226 shares. These awards represent standard director compensation rather than discretionary trading activity.

How many Denali Therapeutics (DNLI) shares does Jennifer Cook hold after this grant?

After the grant, Jennifer Cook directly holds 32,483 shares of Denali Therapeutics Common Stock. This total includes 6,408 unvested restricted stock units that each represent a contingent right to receive one share when vesting conditions are satisfied under the award terms.

What are the terms of Jennifer Cook’s restricted stock units from Denali Therapeutics (DNLI)?

The grant consists of 6,408 restricted stock units, each tied to one share of Common Stock. One hundred percent of the units vest upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders after the grant date.

What are the key details of the stock option granted to Jennifer Cook by Denali Therapeutics (DNLI)?

Jennifer Cook received a stock option for 19,226 shares of Common Stock with an exercise price of $19.66 per share. All option shares will vest upon the earlier of one year from the grant date or the day before Denali’s next annual meeting of stockholders following the grant.

Was Jennifer Cook’s Form 4 transaction in Denali Therapeutics (DNLI) a market buy or sell?

The Form 4 reflects compensation-related acquisitions, not market trades. Both the 6,408 restricted stock units and the 19,226-share stock option were granted to her at a price of $0.00 per share as equity awards for service, rather than open-market buying or selling.